French drug company Sanofi, whose website boasts its products vaccinate over 500 million annually, tumbled nearly 3.5%. With uncertainty over the direction of their agencies, many older scientists at ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

"UK bus market witnesses 36.1% growth in Q3 2024" was originally created and published by Motor Finance Online, a GlobalData ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade ...

Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

Franchise Group, based in Delaware, Ohio, is the parent company of American Freight and other stores including Vitamin ...

At two upcoming events on rare disease clinical trials and data management, experts will dissect the latest trends and ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

The global Medical Nutrition Market is forecasted to experience substantial growth between 2024 and 2034, according to a comprehensive report by Future Market Insights. With an increasing emphasis on ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...